ArticleEBioMedicine2019
Interleukin-18 and outcome after allogeneic stem cell transplantation: A retrospective cohort study.
Article in EBioMedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Associations of Serum ALB, IL-18, and NGAL Levels and Individualized Nutritional Nursing in Patients with Hematopoietic Stem Cell Transplantation and Myelosuppression.Pakistan journal of medical sciences · 2026Article
- Comprehensive assessment of endothelial dysfunction before cellular therapy: EASIX, local imaging, and systemic biomarkers.Blood vessels, thrombosis & hemostasis · 2025Article
- Damage-induced IL-18 stimulates thymic NK cells limiting endogenous tissue regeneration.Nature immunology · 2025Article
- Inflammasomes: potential therapeutic targets in hematopoietic stem cell transplantation.Cell communication and signaling : CCS · 2024Review
- Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants.Frontiers in immunology · 2024Review
- EASIX-1year and late mortality after allogeneic stem cell transplantation.Blood advances · 2023Article
- Role of interleukin-18 in postoperative delirium: an exploratory analysis.British journal of anaesthesia · 2022Article
- Pyroptosis-Induced Inflammation and Tissue Damage.Journal of molecular biology · 2022Review
- Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation.Vaccines · 2022Article
- Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation.Bone marrow transplantation · 2021Review
- Early bilirubinemia after allogeneic stem cell transplantation-an endothelial complication.Bone marrow transplantation · 2021Article
- Long-Term Effects of Allogeneic Hematopoietic Stem Cell Transplantation on Systemic Inflammation in Sickle Cell Disease Patients.Frontiers in immunology · 2021Article
- Article
- EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients.Frontiers in immunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterleukin-18 (IL-18) is involved in endothelial activation and dysfunction, and in the pathogenesis and severity of acute graft-versus-host disease (aGVHD). Its relevance for patient outcome after allogeneic stem cell transplantation (alloSCT) has not yet been comprehensively addressed.
methodsPre-transplant serum levels of free IL-18 were retrospectively assessed in a cohort of 589 patients (training cohort). Results were validated in 688 patients allografted in a different centre. The primary endpoint was overall survival (OS). Secondary endpoints included incidences of non-relapse mortality (NRM), relapse, and aGVHD.
findingsIn the training cohort, higher pre-transplant levels of free IL-18 were significantly associated with worse OS (hazard ratio [HR] per 1-log2 increase, 1.25, P = 0.008) in multivariable models. This was due to a higher hazard of NRM (HR per 1-log2 increase, 1.39, P = 0.001), rather than relapse. The associations of pre-transplant free IL-18 with higher NRM (HR per 1-log2 increase, 1.24, P = 0.02) and shorter OS (HR per 1-log2 increase, 1.22, P = 0.006) were confirmed in the validation cohort. In both cohorts, the correlations of higher pre-transplant free IL-18 serum levels with increased NRM and worse OS were mainly driven by fatal infectious complications. No associations with incidence of aGVHD were observed.
interpretationHigher pre-transplant levels of free IL-18 were associated with non-relapse and overall mortality after alloSCT. Our results may provide a rationale for prospective studies evaluating IL-18 status and inhibition of IL-18 activity in patients undergoing allografting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.